Fundamental Analysis of BICYCLE THERAPEUTICS PLC-ADR(NASDAQ:BCYC) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to BCYC. BCYC was compared to 568 industry peers in the Biotechnology industry. While BCYC has a great health rating, there are worries on its profitability. BCYC shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BCYC has reported negative net income.

BCYC had a negative operating cash flow in the past year.

BCYC had negative earnings in each of the past 5 years.

In the past 5 years BCYC always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -16.68%, BCYC belongs to the top of the industry, outperforming 80.35% of the companies in the same industry.

BCYC's Return On Equity of -20.01% is amongst the best of the industry. BCYC outperforms 84.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.68%
ROE	-20.01%
ROIC	N/A

ROA(3y)-23.91%

ROA(5y)-26.23%

ROE(3y)-36.54%

ROE(5y)-39.18%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCYC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BCYC has more shares outstanding

The number of shares outstanding for BCYC has been increased compared to 5 years ago.

Compared to 1 year ago, BCYC has an improved debt to assets ratio.

2.2 Solvency

BCYC has an Altman-Z score of 3.38. This indicates that BCYC is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 3.38, BCYC is doing good in the industry, outperforming 75.93% of the companies in the same industry.

There is no outstanding debt for BCYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.38

ROIC/WACCN/A

WACC8.79%

2.3 Liquidity

A Current Ratio of 17.13 indicates that BCYC has no problem at all paying its short term obligations.

With an excellent Current ratio value of 17.13, BCYC belongs to the best of the industry, outperforming 92.04% of the companies in the same industry.

A Quick Ratio of 17.13 indicates that BCYC has no problem at all paying its short term obligations.

BCYC has a Quick ratio of 17.13. This is amongst the best in the industry. BCYC outperforms 92.04% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	17.13
Quick Ratio	17.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BCYC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.94%, which is quite impressive.

The Revenue has grown by 48.54% in the past year. This is a very strong growth!

Measured over the past years, BCYC shows a very strong growth in Revenue. The Revenue has been growing by 30.45% on average per year.

EPS 1Y (TTM)33.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%41.27%

Revenue 1Y (TTM)48.54%

Revenue growth 3Y37.44%

Revenue growth 5Y30.45%

Sales Q2Q%-50%

3.2 Future

BCYC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.82% yearly.

Based on estimates for the next years, BCYC will show a very strong growth in Revenue. The Revenue will grow by 64.72% on average per year.

EPS Next Y39.66%

EPS Next 2Y13.83%

EPS Next 3Y6.68%

EPS Next 5Y12.82%

Revenue Next Year22.38%

Revenue Next 2Y0.52%

Revenue Next 3Y20.41%

Revenue Next 5Y64.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BCYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y13.83%

EPS Next 3Y6.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BCYC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (12/18/2024, 11:34:50 AM)

15.62

+0.48 (+3.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.08B

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.68%
ROE	-20.01%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	17.13
Quick Ratio	17.13
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)33.94%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y39.66%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)48.54%

Revenue growth 3Y37.44%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BICYCLE THERAPEUTICS PLC-ADR (BCYC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens